AcariaHealth (Acaria) has been selected to dispense ENTYVIO in the form of a pre-filled, single-dose subcutaneous injection pen for adults seeking maintenance treatment for moderate to severe ulcerative colitis (UC). The ability to dispense this drug will expand access to patients with limited treatment options.

“AcariaHealth is proud to provide patients with access to ENTYVIO, bringing flexible administration options to those living with UC,” said Vice President of Pharma Business Development at AcariaHealth, Steve Granzyk. “This reflects our commitment to improving outcomes and positively impacting patients’ quality of life.”

Ulcerative colitis is a chronic, inflammatory bowel disease that can cause severe pain, bleeding, diarrhea and other symptoms, as well as increased risk of colon cancer. With ENTYVIO in-network, AcariaHealth expands access to leading therapy options that improve administration flexibility without compromising efficacy.

Click here to view full prescribing information for ENTYVIO.